The nation of Zimbabwe has declined a substantial American health deal worth $367m (272 million pounds) over five years due to the United States' request for sensitive data.
This rejection became public after a internal memorandum from December was leaked, revealing that Head of State Emmerson Mnangagwa felt the deal was "unbalanced".
A government spokesman later stated that the US was seeking biological samples for research and profit while refused to guarantee the resulting advantages from any future vaccines.
"We must now begin the difficult and regrettable process of winding down our health aid in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy said the US had furnished over $1.9bn as health assistance to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has urged further negotiations to reach a deal suitable to both sides so the country's vital HIV treatment initiative can be sustained.
Broader Implications
This rejection follows a comparable situation in Kenya, where a high court suspended a similar health funding agreement after concerns were filed about the security of Kenyans' medical information.
After resuming office last year, US President Donald Trump has reduced overseas assistance and shut down the key foreign aid agency.
The agency had overseen assistance for the US government, but Trump stated its spending was "inefficient" and his administration was pursuing direct bilateral deals to enhance transparency and responsibility.
As per statements, 16 nations in Africa have so far agreed to similar agreements, representing over $18.3bn of fresh investment.
Details of the Rejected Agreement
The money for Zimbabwe would have gone towards "combating HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this cooperation could have provided immense advantages for the people of Zimbabwe, particularly the 1.2 million presently on HIV treatment via American-funded initiatives," the Ambassador added.
However, official spokesman Nick Mangwana maintained the arrangement was "unequal".
"Our nation was requested to provide its biological resources and data indefinitely, with no equivalent promise of benefiting from any medical innovations – such as new medicines or tests – that could be developed from that shared data," his statement read.
"Put simply, our country would provide the basic resources for scientific discovery with no certainty that the resulting innovations would be accessible to our population if a future pandemic arise."
Sovereignty and Global Health
He also noted that the American exit from the World Health Organization (WHO) and its pursuit of one-on-one health agreements were undermining structures already set up through the global organization.
Mangwana gave as an example its Pathogen Access and Benefit Sharing framework created to manage future pandemics.
"This framework is designed to ensure that when a nation contributes its samples, the benefits – including medicines and cures – are shared equitably, not monopolised solely by those with the capability to create them."
The government's concerns regarding the US deal "must not be interpreted as anti-American sentiment," he added.
"We are open to further discussions with our US partners on how subsequent collaboration could be structured in a way that respects the sovereignty and dignity of each country."
Medical Community Reaction
A leading public health body expressed it understood the government's concerns, but recommended that negotiations need to persist given that much of the nation's HIV programmes relied on foreign aid.
"If specific concerns exist, including those relating to data governance or implementation frameworks, these can frequently be resolved through technical clarification and mutually agreed protections," it said.
The situation underscores the continuing challenges between receiving crucial foreign assistance and safeguarding a country's data in an ever more data-driven world.